Increasing local levels of neuregulin (glial growth factor‐2) by direct infusion into areas of demyelination does not alter remyelination in the rat CNS

Glial growth factor‐2 (GGF‐2) is a neuronally derived isoform of neuregulin shown in vitro to promote proliferation and survival of oligodendrocytes, the myelinating cells of the CNS. Enhanced remyelination has been demonstrated in vivo following systemic delivery of human recombinant GGF‐2 (rhGGF‐2) in experimental autoimmune encephalomyelitis (EAE). However, it is uncertain whether this is the result of direct effects of rhGGF‐2 on cells of the oligodendrocyte lineage or due to modulation of the immune or inflammatory response. If this enhanced remyelination was due to direct effects of rhGGF‐2 on cells of the oligodendrocyte lineage then one would expect rhGGF‐2 to induce a similar proremyelinating response in nonimmune, gliotoxin models of demyelination. Using a gliotoxin model of demyelination we were therefore able to ascertain the in vivo effect of rhGGF‐2 following local CNS delivery in a model that is not confounded by the concurrent presence of an immune‐mediated process. No significant alteration in the rate or character of remyelination was evident following local delivery as compared to controls, and indeed nor following systemic delivery in the gliotoxin model. The results of this study therefore indicate that both direct infusion and systemic delivery of rhGGF‐2 do not alter remyelination in a nonimmune, gliotoxin model of demyelination. This suggests that the proremyelinating effects of systemically delivered rhGGF‐2 in EAE are unlikely to be due to direct effects on the oligodendrocyte lineage, but may be mediated by rhGGF‐2 inducing an environment more favourable to remyelination, possibly through modulation of the immune response.

[1]  R. Franklin,et al.  Impaired remyelination and depletion of oligodendrocyte progenitors does not occur following repeated episodes of focal demyelination in the rat central nervous system. , 2003, Brain : a journal of neurology.

[2]  A. Bruce-Keller,et al.  The neuregulin GGF2 attenuates free radical release from activated microglial cells , 2003, Journal of Neuroimmunology.

[3]  C. ffrench-Constant,et al.  Regulation of Integrin Growth Factor Interactions in Oligodendrocytes by Lipid Raft Microdomains , 2003, Current Biology.

[4]  C. ffrench-Constant,et al.  CNS integrins switch growth factor signalling to promote target-dependent survival , 2002, Nature Cell Biology.

[5]  Robin J. M. Franklin,et al.  Why does remyelination fail in multiple sclerosis? , 2002, Nature Reviews Neuroscience.

[6]  Chao Zhao,et al.  Expression of the POU-Domain Transcription Factors SCIP/Oct-6 and Brn-2 Is Associated with Schwann Cell but Not Oligodendrocyte Remyelination of the CNS , 2002, Molecular and Cellular Neuroscience.

[7]  Chao Zhao,et al.  The Age-Related Decrease in CNS Remyelination Efficiency Is Attributable to an Impairment of Both Oligodendrocyte Progenitor Recruitment and Differentiation , 2002, The Journal of Neuroscience.

[8]  R. Franklin,et al.  Increasing Local Levels of IGF-I mRNA Expression Using Adenoviral Vectors Does Not Alter Oligodendrocyte Remyelination in the CNS of Aged Rats , 2002, Molecular and Cellular Neuroscience.

[9]  R. Franklin,et al.  Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin‐induced demyelination , 2001, Glia.

[10]  K. Murray,et al.  Neuregulin Signaling Regulates Neural Precursor Growth and the Generation of Oligodendrocytes In Vitro , 2001, The Journal of Neuroscience.

[11]  J. Salzer,et al.  Glial Growth Factor/Neuregulin Inhibits Schwann Cell Myelination and Induces Demyelination , 2001, The Journal of cell biology.

[12]  H. Neumann,et al.  Anti‐inflammatory activity of nerve growth factor in experimental autoimmune encephalomyelitis: inhibition of monocyte transendothelial migration , 2001, European journal of immunology.

[13]  J. Antel,et al.  Neuregulins and erbB receptor expression in adult human oligodendrocytes , 2000, Glia.

[14]  C. Birchmeier,et al.  Neuregulin, a factor with many functions in the life of a Schwann cell , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[15]  R. Franklin,et al.  The re-expression of the homeodomain transcription factor Gtx during remyelination of experimentally induced demyelinating lesions in young and old rat brain , 2000, Neuroscience.

[16]  D. Pitt,et al.  Insulin-like growth factor-1 fails to enhance central nervous system myelin repair during autoimmune demyelination. , 2000, American Journal of Pathology.

[17]  P. Villoslada,et al.  Human Nerve Growth Factor Protects Common Marmosets against Autoimmune Encephalomyelitis by Switching the Balance of T Helper Cell Type 1 and 2 Cytokines within the Central Nervous System , 2000, The Journal of experimental medicine.

[18]  C. ffrench-Constant,et al.  Integrins mediate a neuronal survival signal for oligodendrocytes , 1999, Current Biology.

[19]  R. Franklin,et al.  Remyelination occurs as extensively but more slowly in old rats compared to young rats following gliotoxin‐induced CNS demyelination , 1999, Glia.

[20]  P. Canoll,et al.  GGF/Neuregulin Induces a Phenotypic Reversion of Oligodendrocytes , 1999, Molecular and Cellular Neuroscience.

[21]  R. Franklin,et al.  Demyelination and remyelination of the caudal cerebellar peduncle of adult rats following stereotaxic injections of lysolecithin, ethidium bromide, and complement/anti‐galactocerebroside: A comparative study , 1999, Glia.

[22]  Robert H. Miller,et al.  Failure of spinal cord oligodendrocyte development in mice lacking neuregulin. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[23]  C. Raine,et al.  The neuregulin, glial growth factor 2, diminishes autoimmune demyelination and enhances remyelination in a chronic relapsing model for multiple sclerosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[24]  R. Franklin,et al.  Growth factors and remyelination in the CNS. , 1997, Histology and histopathology.

[25]  P. Canoll,et al.  GGF/Neuregulin Is a Neuronal Signal That Promotes the Proliferation and Survival and Inhibits the Differentiation of Oligodendrocyte Progenitors , 1996, Neuron.

[26]  B. Stokes,et al.  Analysis of TGF-β1 gene expression in contused rat spinal cord using quantitative RT-PCR , 1995 .

[27]  H. Webster,et al.  Insulin-like growth factor I treatment reduces demyelination and up-regulates gene expression of myelin-related proteins in experimental autoimmune encephalomyelitis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[28]  G. Fischbach,et al.  A role for the acetylcholine receptor-inducing protein ARIA in oligodendrocyte development. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Joseph Schlessinger,et al.  Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.

[30]  F. Mcmorris,et al.  Insulin‐like growth factor I promotes cell proliferation and oligodendroglial commitment in rat glial progenitor cells developing in vitro , 1988, Journal of neuroscience research.

[31]  D. McFarlin,et al.  Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice , 1984, Nature.

[32]  M. Raff,et al.  Studies on cultured rat Schwann cells. I. Establishment of purified populations from cultures of peripheral nerve , 1979, Brain Research.

[33]  A. Hirano,et al.  Remyelination in multiple sclerosis with peripheral type myelin. , 1973, Archives of neurology.

[34]  E. Anton,et al.  Molecular mechanisms of interactions between radial glia and neurons. , 2001, Progress in brain research.

[35]  P. Tofilon,et al.  Neuregulin in neuron/glial interactions in the central nervous system. GGF2 diminishes autoimmune demyelination, promotes oligodendrocyte progenitor expansion, and enhances remyelination. , 1999, Advances in experimental medicine and biology.

[36]  D. Pleasure,et al.  Protein growth factors as potential therapies for central nervous system demyelinative disorders , 1994, Annals of neurology.